昊海生科(688366.SH)公告称，公司控股股东、实际控制人之一蒋伟收到中国证监会出具的《行政处罚 事先告知书》，涉及的事项与公司无关。蒋伟不参与公司日常经营管理，该事项不会对公司日常经营、 业务及财务造成重大影响。行政处罚最终结果将以中国证监会对蒋伟最终出具的《行政处罚决定书》结 论为准。 ...

Core Insights - The biopharmaceutical industry is experiencing an upward trend, with companies showcasing their R&D progress and global market strategies during the recent performance briefing [1] - Companies are optimistic about their development in the second half of the year, driven by high R&D investments and technological advancements [1][4] R&D Progress - Companies like Sailun Biopharma and Haohai Biological are making steady progress in product development and market expansion [1] - Sailun Biopharma plans to introduce new projects, including broad-spectrum anti-snake venom antibodies and recombinant snake venom coagulants by mid-2025 [1][2] - Haohai Biological has several innovative products in the pipeline, including a pain-free cross-linked hyaluronic acid gel for aesthetic medicine, which has entered the registration phase [2] Market Trends - The demand for algal oil DHA products is increasing, driven by the replacement of old national standards for infant formula and rising maternal and infant consumption [2][3] - Jia Bi You's sales of algal oil DHA are growing significantly, with a faster transition from fish oil DHA among major clients [3] Industry Outlook - Companies express confidence in the industry's performance in the second half of the year, with expectations of continued growth in the GLP-1 drug market due to its effectiveness in diabetes and weight loss [4] - Nawei Technology anticipates significant market expansion for GLP-1 and other peptide drugs, projecting a revenue increase of approximately 108% in the first half of 2025 [4] Innovation and Global Expansion - The demand for drug molecular building blocks is recovering, with companies like Bid Pharma expanding their compound libraries to cover mainstream targets [5] - Companies are leveraging AI in synthetic biology to enhance R&D efficiency and reduce costs [5] - Xuan Tai Pharmaceutical is pursuing a diversified market strategy, collaborating with Kalbe Farma in Indonesia to penetrate Southeast Asian markets [6]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06826 | 說明 | H 股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | ...

Group 1: Macro Insights - The report highlights six key focuses in recent policies, including the planning of the "15th Five-Year Plan" and upcoming US-China talks, indicating a short-term policy stance of "holding back but not lifting" with potential for future stimulus [4] - August's new credit scale fell below expectations and seasonal norms, primarily due to weakened government bond support and a slowdown in social financing growth, suggesting continued weakness in consumption and real estate [5] - The US August CPI data met expectations, but initial jobless claims surged to a near two-year high, increasing the likelihood of Fed rate cuts in September and October [6] Group 2: Real Estate and Construction - The real estate market confirmed a weekly level increase, with a rebound of over 20% since April 7, indicating a potential nearing of the end of this upward trend [6][7] - The report emphasizes the importance of monitoring domestic coal supply and the recovery of Mongolian coal imports, as well as potential strong stimulus policies [30] - The construction materials sector is expected to benefit from early issuance of debt limits and measures to alleviate hidden debts, with a focus on municipal engineering projects [40] Group 3: Financial Sector - The banking sector continues to face an asset shortage, with a slowdown in social financing growth indicating a decline in asset supply, while deposit growth remains lower than social financing [17] - The report notes that the average issuance rate for 1-year time deposits has increased, reflecting a tightening in the funding environment [20] Group 4: Energy and Commodities - The report indicates a strong outlook for metal prices, particularly copper, driven by seasonal demand and anticipated interest rate cuts [44] - The renewable energy sector is poised for growth with new pricing policies aimed at rationalizing cost sharing, which could catalyze the development of green electricity projects [45] Group 5: AI and Technology - The report discusses the emergence of AI infrastructure, particularly in the context of DeepSeek technology, which is expected to drive significant advancements in the AI sector and reshape global perceptions of Chinese tech capabilities [10][11] - The AI industry is projected to be driven by both model advancements and application implementations, with major tech companies expected to continue releasing new models [13]

Core Insights - The article discusses the evolution of policies supporting the development of the biomedical materials industry in China, highlighting a shift from basic research support to industrialization, innovation-driven growth, and high-quality development [1][3]. Policy Overview - Since 2015, multiple government departments, including the State Council and the National Health Commission, have issued various policies to support and regulate the biomedical materials industry, focusing on technology development, industry upgrades, quality standards, and centralized procurement [3][4]. - Key policies include the 2024 notification on centralized procurement of high-value medical consumables, aimed at enhancing procurement efficiency and reducing costs [4][5]. - The "14th Five-Year Plan" emphasizes the development of high-end medical devices and key technologies, aiming to improve supply capabilities and address gaps in high-end medical equipment [9][10]. Development Goals - The focus is on technological innovation in high-end implantable products, such as biodegradable vascular stents and artificial joints, as well as new materials like recombinant collagen and biodegradable materials [8][9]. - The government aims to optimize approval processes, promote bulk procurement, and enhance collaboration among academia, industry, and healthcare to boost competitiveness and domestic production levels [8][10]. - By 2025, the goal is to achieve comprehensive coverage of DRG/DIP payment methods in all eligible medical institutions, ensuring a more efficient healthcare financing system [10]. Regional Policies - Various provinces have introduced policies to promote the biomedical materials industry, with a focus on centralized procurement for orthopedic implants and other high-value medical consumables [12][13]. - Cities like Beijing and Shanghai are encouraging the development of new biomedical materials and technologies, including advanced manufacturing techniques and 3D bioprinting [13][14]. - The policies aim to strengthen the local manufacturing capabilities and foster innovation in the biomedical materials sector [14][17].

Core Viewpoint - The Chinese medical hydrogel industry is projected to reach a market size of approximately 650 million yuan in 2024, reflecting a year-on-year growth of 4.84%, driven by the gradual application of advanced medical technologies in key healthcare areas [1][8]. Industry Overview - Medical hydrogels are three-dimensional network structures formed from hydrophilic polymers, characterized by high water absorption, biocompatibility, and the ability to maintain a moist environment. They can be modified to possess specific properties such as self-healing and environmental responsiveness [2][4]. Market Size - The global medical hydrogel market is expected to reach approximately 2.292 billion USD in 2024, with a year-on-year growth of 2.79%. The increasing demand for chronic wound management, particularly among the elderly population, is driving the application of medical hydrogels in wound care, drug delivery, and tissue engineering [8][9]. Key Enterprises - The industry is characterized by a competitive landscape where leading companies dominate, and specialized firms focus on niche areas. Changchun Jiyuan Biological, a leader in the high-end hydrogel market, offers a range of products including wound dressings and eye therapy patches, while Huayang Medical specializes in silicone gel and hemostatic materials [9][10][12]. Industry Development Trends 1. **Technological Innovation**: The future of the medical hydrogel industry in China will focus on the integration of smart responsive materials and bioprinting technology. For instance, the innovative cervical cancer radiotherapy protective hydrogel by Ruining Bio has gained clinical attention [12][13]. 2. **Market Demand Expansion**: The growth of the medical hydrogel market is primarily driven by the aging population and the expansion of regenerative medicine applications. The demand for moist healing dressings is expected to rise significantly due to the increasing prevalence of chronic wounds [13][14]. 3. **Regulatory Environment and Competition**: Stricter industry regulations and local technological advancements are shaping a competitive landscape. Domestic companies are leveraging cost advantages to replace international brands, while also expanding into overseas markets [14][15].

2025 中報 目 錄 | | 頁數 | | --- | --- | | 公司資料 | 2 | | 中期業績摘要 | 4 | | 管理層討論與分析 | 5 | | 中期簡明綜合損益及其他綜合收益表 | 22 | | 中期簡明綜合財務狀況表 | 24 | | 中期簡明綜合權益變動表 | 26 | | 中期簡明綜合現金流量表 | 28 | | 中期簡明綜合財務報表附註 | 30 | | 其他資料 | 52 | | 釋義 | 62 | | 技術詞彙 | 65 | 執行董事： 侯永泰博士 （主席） 吳劍英先生 （總經理） 陳奕奕女士 唐敏捷先生 （財務總監） 非執行董事： 游捷女士 黃明先生 魏長征先生 （職工代表） 獨立非執行董事： 沈紅波先生 姜志宏先生 蘇治先生 楊玉社先生 授權代表 黃明先生 趙明璟先生 公司資料 第六屆董事會 蘇治先生 （主席） 吳劍英先生 黃明先生 姜志宏先生 沈紅波先生 提名委員會 姜志宏先生 （主席） 侯永泰博士 沈紅波先生 蘇治先生 游捷女士 聯席公司秘書 田敏女士 趙明璟先生 （香港公司治理公會資深會員） 審計委員會 沈紅波先生 （主席） 姜志宏先生 蘇治先生 楊玉社先生 游捷女士 ...

Group 1 - The company, Haohai Biological Technology, announced its participation in a collective performance briefing for the biopharmaceutical and CXO industry hosted by the Shanghai Stock Exchange [2] - The event is scheduled for September 15, 2025, from 15:00 to 17:00 [2]

Group 1 - The company, Shanghai Haohai Biological Technology Co., Ltd., will participate in the 2025 semi-annual performance briefing for the biopharmaceutical and CXO industry organized by the Shanghai Stock Exchange to enhance communication with investors [1][2] - The performance briefing is scheduled for September 15, 2025, from 15:00 to 17:00, and will be conducted via video live streaming and online interaction [1][2] - Investors are encouraged to submit questions from September 8 to September 12, 2025, through the Shanghai Stock Exchange Roadshow Center website or via the company's email [2] Group 2 - Key participants in the briefing will include the company's chairman, general manager, financial officer, independent directors, and the board secretary, although adjustments may occur due to special circumstances [2] - After the briefing, investors can access the main content and details of the event through the Shanghai Stock Exchange Roadshow Center [2]

证券代码：688366 证券简称：昊海生科 公告编号：2025-041 上海昊海生物科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、说明会类型 上海昊海生物科技股份有限公司（以下简称"公司"）已于 2025 年 8 月 23 日在上海证券交易所网站（www.sse.com.cn）披露了《上海昊海生物科技股份有 限公司 2025 年半年度报告》。为加强与投资者的深入交流，使投资者更加全面、 深入地了解公司情况，公司参加由上海证券交易所主办的 2025 年半年度科创板 生物制品及 CXO 行业集体业绩说明会（以下简称"本次业绩说明会"），此次活 动将以视频直播和网络互动的方式召开，欢迎广大投资者积极参与。公司现就本 次业绩说明会提前向广大投资者征集相关问题，广泛听取投资者的意见和建议。 二、说明会召开的时间及方式 本次业绩说明会将于 2025 年 9 月 15 日（星期一）15:00-17:00 在上证路演 会议召开时间：2025 年 9 月 15 日（星期一）15:00-17:00 会议 ...